Literature DB >> 28319603

Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings.

Dimple Patel1, K T Park.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28319603      PMCID： PMC5524607          DOI： 10.1097/MPG.0000000000001572

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN： 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  19 in total

1.  Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.

Authors:  J Sieczkowska; D Jarzębicka; A Banaszkiewicz; A Plocek; A Gawronska; E Toporowska-Kowalska; G Oracz; M Meglicka; J Kierkus
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

2.  Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.

Authors:  Shomron Ben-Horin; Miri Yavzori; Itai Benhar; Ella Fudim; Orit Picard; Bella Ungar; SooYoung Lee; SungHwan Kim; Rami Eliakim; Yehuda Chowers
Journal:  Gut       Date:  2015-04-20       Impact factor: 23.059

3.  A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia.

Authors:  Valentin Brodszky; Fanni Rencz; Márta Péntek; Petra Baji; Péter L Lakatos; László Gulácsi
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-07-10       Impact factor: 2.217

Review 4.  Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review.

Authors:  Elaine Nguyen; Erin R Weeda; Diana M Sobieraj; Brahim K Bookhart; Catherine Tak Piech; Craig I Coleman
Journal:  Curr Med Res Opin       Date:  2016-04-01       Impact factor: 2.580

Review 5.  Biosimilars in Crohn's Disease and Ulcerative Colitis.

Authors:  Douglas C Wolf
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

Review 6.  Biosimilars for the management of rheumatoid arthritis: economic considerations.

Authors:  László Gulácsi; Valentin Brodszky; Petra Baji; HoUng Kim; Su Yeon Kim; Yu Young Cho; Márta Péntek
Journal:  Expert Rev Clin Immunol       Date:  2015       Impact factor: 4.473

7.  The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.

Authors:  Bella Ungar; Yehuda Chowers; Miri Yavzori; Orit Picard; Ella Fudim; Ofir Har-Noy; Uri Kopylov; Rami Eliakim; Shomron Ben-Horin
Journal:  Gut       Date:  2013-09-16       Impact factor: 23.059

8.  Natural history of pediatric Crohn's disease: a population-based cohort study.

Authors:  Gwenola Vernier-Massouille; Mamadou Balde; Julia Salleron; Dominique Turck; Jean Louis Dupas; Olivier Mouterde; Véronique Merle; Jean Louis Salomez; Julien Branche; Raymond Marti; Eric Lerebours; Antoine Cortot; Corinne Gower-Rousseau; Jean Frédéric Colombel
Journal:  Gastroenterology       Date:  2008-07-03       Impact factor: 22.682

Review 9.  Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review.

Authors:  Francine Chingcuanco; Jodi B Segal; Seoyoung C Kim; G Caleb Alexander
Journal:  Ann Intern Med       Date:  2016-08-02       Impact factor: 25.391

Review 10.  Clinical experience with Zarzio® in Europe: what have we learned?

Authors:  Pere Gascón; Hans Tesch; Karl Verpoort; Maria Sofia Rosati; Nello Salesi; Samir Agrawal; Nils Wilking; Helen Barker; Michael Muenzberg; Matthew Turner
Journal:  Support Care Cancer       Date:  2013-08-01       Impact factor: 3.603
View more
  2 in total

Review 1.  Biosimilars in Pediatric IBD: Updated Considerations for Disease Management.

Authors:  Valeria Dipasquale; Ugo Cucinotta; Claudio Romano
Journal:  Biologics       Date:  2022-06-13

2.  Patients' beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch.

Authors:  Chiara Gasteiger; Maria Lobo; Nicola Dalbeth; Keith J Petrie
Journal:  Rheumatol Int       Date:  2020-04-16       Impact factor: 2.631
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.